Sirius Medical Debuts at Major U.S. Breast Surgeons Conference

Introducing Pintuition® powered by GPSDetectTM for surgical navigation that simply makes sense

Sirius Medical has announced their participation at the American Society of Breast Surgeons 23rd Annual Meeting, April 6-10 at the Wynn Las Vegas Resort. Sirius Medical, a leader in tumor navigation technology, will debut Pintuition powered by GPSDetect, a unique navigation system to locate and excise non-palpable breast lesions.

Sirius Medical Debuts At Major U.s. Breast Surgeons Conference

Pintuition is CE marked and FDA 510(k) cleared and over 2,500 procedures have been performed worldwide. The system is an intuitive, wire-free, surgical navigation system with multisensory GPSDetect that provides real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors easily and accurately.

“Pintuition is true navigation technology,” said Barry Rosen, MD, FACS, oncologist, Chicago, IL. “While localization gives direction, this system provides me with distance, direction, and precise location. It is simple and intuitive.”

In addition to technology innovation, Sirius Medical has a strong passion for value-based healthcare. Aiming to improve sustainable access to innovative surgical cancer care worldwide, Sirius Medical has developed unique financial models and SiriusLinkTM, to help physicians and hospitals manage growth and control costs. SiriusLink is an innovative data science application that enables hospital teams to achieve process improvement.

Bart Vrouenraets, MD, PhD, surgeon and head of the department of quality at the OLVG Hospital, Netherlands, will present a poster, SiriusLink – Surgical Oncology Process Improvement, at the conference on April 7th.

“We are excited to be a part of this premier breast surgeon conference,” says Bram Schermers, CEO Sirius Medical. “In the short time we have been in the U.S. market, physicians and administrators are embracing our technology and its simplicity, precision and affordability.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy